Paris, France

Francis E Rose

This inventor holds 1 USPTO granted patent. Top assignee: Metabio Joullie. Active years: 1980.


% Patents Active = 100.0

Average Co-Inventor Count = 5.0

ph-index = 1

Forward Citations = 6(Granted Patents)


Company Filing History:


Years Active: 1980

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Francis E. Rose: Innovator in Therapeutic Compounds

Introduction

Francis E. Rose is a notable inventor based in Paris, France. He has made significant contributions to the field of medicinal chemistry, particularly in the development of therapeutic compounds. His work focuses on creating innovative solutions that have practical applications in healthcare.

Latest Patents

Francis E. Rose holds a patent for "Therapeutically useful N-phenylaniline derivatives." This patent includes compounds of a specific general formula, where Ar represents a phenyl group that may be unsubstituted or substituted by a halogen atom or a lower alkyl group. The compounds have demonstrated therapeutic utility, especially as analgesics, making them valuable in pain management.

Career Highlights

Throughout his career, Francis E. Rose has been dedicated to advancing the field of pharmacology. His innovative approach to developing new compounds has led to the successful patenting of his work. He is associated with Metabio Joullie, a company that focuses on biopharmaceutical research and development.

Collaborations

Francis has collaborated with notable colleagues, including Christian J. Warolin and Pierre Muller. These partnerships have fostered a collaborative environment that enhances the research and development of therapeutic compounds.

Conclusion

Francis E. Rose's contributions to the field of medicinal chemistry are noteworthy, particularly his patented work on N-phenylaniline derivatives. His innovative spirit and collaborative efforts continue to impact the healthcare industry positively.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…